Table 3. . Parkinson's Disease Biomarker Program project categorization summary.
| Investigator | Biomarkers purpose | Project title | Scientific field | Subfield (focus) | Research funding announcement |
|---|---|---|---|---|---|
| Albin |
Diagnostic |
Serotonin and amyloidopathy |
Imaging |
PET imaging, serotonergic innverative and a-beta deposition, PD versus aging |
Research project grant (Parent R01)† |
| Alcalay |
Prognostic |
The role of glucocerebrosidase in Parkinson's disease |
Genome and transcriptome |
Risk assessment PD in GBA mutation carriers |
Independent Scientist Award (Parent K02)† |
| Ascherio |
Susceptibility/risk |
Metabolomics and risk of Parkinson's disease |
Proteome and metabolome |
Lifestyle and risk for PD |
Research project grant (Parent R01)† |
| Bowman |
Prognostic |
Analytic methods for determining multimodal biomarkers for Parkinson's disease |
Multimodal (clinical, imaging) |
Statisical techniques to differentiate PD from controls, AD |
Exploratory laboratory and analysis projects in Parkinson's disease biomarkers (U18) |
| Chen-Plotkin |
Prognostic, susceptibility/risk |
Unbiased approaches to novel biomarker discovery in Parkinson's disease |
Proteome and metabolome |
Plasma-based markers for cognitive performance/risk |
Studies in Parkinson's disease biomarkers discovery (U01) |
| Dawson; Rosenthal |
Resource creation, subject characterization |
Johns Hopkins medicine biomarker discovery in Parkinson's disease |
Clinical |
Cohort assessment and collection |
Studies in Parkinson's disease biomarkers discovery (U01) |
| Dewey |
Resource creation, subject characterization |
Diagnostic and prognostic biomarkers for Parkinson's disease |
Clinical |
Cohort assessment and collection, gait and balance as rate biomarkers |
Studies in Parkinson's disease biomarkers discovery (U01) |
| German |
Diagnostic |
Diagnostic and prognostic biomarkers for Parkinson's disease |
Proteome and Metabolome |
Peptoid identification to differentiate PD vs AD, PD vs controls |
Studies in Parkinson's disease biomarkers discovery (U01) |
| Huang |
Diagnostic, prognostic, progression |
Multimodal MRI markers of nigrostriatal pathology in Parkinson's disease |
Imaging |
DTI and MRI measures of iron-related proteins; PD vs PDism |
Studies in Parkinson's disease biomarkers discovery (U01) |
| Petyuk |
Diagnostic |
Development of Lewy bodies biofluid signatures by targeted proteomics |
Proteome and metabolome |
Identify proteins in pathologically confirmed LB cases; validate in PD/control blood-based sample |
Exploratory laboratory and analysis projects in Parkinson's disease biomarkers (U18) |
| Potashkin |
Diagnostic |
Blood RNA biomarkers of Parkinsons disease and progressive supranuclear palsy |
Genome and transcriptome |
Identify an RNA signature that differentiates PD from PSP |
Parkinson's Disease Biomarker Program discovery projects (U01) |
| Saunders–Pullman |
Diagnostic, progression |
Evaluation of glucocerebrosidase pathway biomarkers in Parkinson disease |
Proteome and metabolome |
Evaluate GBA pathway markers in GBA-PD, IPD, controls and their clinical correlates |
Parkinson's Disease Biomarker Program discovery projects (U01) |
| Scherzer |
Diagnostic |
Biomarkers for early intervention in Parkinson disease |
Genome and transcriptome |
Regulatory RNA studies of PD pathogenesis (neuropathology), blood and spinal fluid of PD cases |
Studies in Parkinson's disease biomarkers discovery (U01) |
| Scherzer |
Prognostic |
Parkinson disease: predicting the future |
Genome and transcriptome |
Exome sequencing to analyze variants that disrupt susceptibility and familial PD genes |
Parkinson's Disease Biomarker Program discovery projects (U01) |
| Vaillancourt |
Diagnostic, prognostic |
Noninvasive markers of neurogeneration in movement disorders |
Imaging |
DTI to differentiate PD from PDism, ET and controls and measure progression |
Biomarkers discovery in Parkinsonism (U01) |
| Vaillancourt; Corcos |
Diagnostic, prognostic |
Neuroimaging biomarkers in Parkinsonism: differentiating subtypes and tracking disease progression |
Imaging |
Using free-water and task-fMRI to compare PD, PDism and controls |
Exclude this? Please see comment |
| Walt |
Diagnostic |
Detection of post-translationally modified proteins as a biomarker panel for Parkinson's disease |
Genome and transcriptome |
Use SiMoA assays to detect and quantify post-translationally modified proteins, to compare PD, PDism and controls |
Parkinson's Disease Biomarker Program discovery projects (U01) |
| West |
Prognostic |
LRRK2 and other novel exosome proteins in Parkinsons disease |
Proteome and metabolome |
Determine if urinary exosome proteins are associated with PD susceptibility and progression |
Exploratory laboratory and analysis projects in Parkinson's disease biomarkers (U18) |
| West |
Prognostic |
Exosome LRRK2 in predicting Parkinson disease phenotypes |
Proteome and metabolome |
Determine if pS(1292)-LRRK2 levels can predict the risk of PD in LRRK2 carriers, and if it can predict progression in IPD |
Parkinson's Disease Biomarker Program discovery projects (U01) |
| Zhang | Diagnostic | Large-scale biomarker discovery and validation for Parkinson's disease | Proteome and metabolome | Use protein and peptide-based approaches to discovery, replicate and validate markers to differentiate PD from controls | Studies in Parkinson's disease biomarkers discovery (U01) |
Comment: the last column illustrates that majority of the projects in the Parkinson's disease biomarkers discovery are because of initiatives coordinated by program officers.
†Unsolicited projects.
AD: Alzheimer's disease; ET: Essential tremor; GBA: Glucocerebrosidase; IPD: Idiopathic Parkinson's disease; PD: Parkinson's disease; PDism: Non-PD Parkinsonism; PET: Positron emission tomography; PSP: Progressive supranuclear palsy.